Skye Bioscience (SKYE) News Today $2.37 +0.03 (+1.28%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$2.37 0.00 (-0.21%) As of 06/10/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SKYE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Cantor Fitzgerald Predicts Skye Bioscience FY2026 EarningsSkye Bioscience, Inc. (NASDAQ:SKYE - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Skye Bioscience in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings per share of ($1June 10 at 8:30 AM | marketbeat.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Rating of "Buy" by AnalystsJune 8 at 2:13 AM | americanbankingnews.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Rating of "Buy" from AnalystsShares of Skye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) have been assigned an average rating of "Buy" from the six brokerages that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-monthJune 8 at 2:11 AM | marketbeat.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by BrokeragesShares of Skye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) have earned an average rating of "Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerJune 8 at 2:11 AM | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Trading Up 24% - Here's What HappenedSkye Bioscience (NASDAQ:SKYE) Trading Up 24% - Here's What HappenedMay 31, 2025 | marketbeat.comLeo Miller: Page 6May 25, 2025 | entrepreneur.comSkye Bioscience to Participate in Upcoming Investment ConferencesMay 22, 2025 | globenewswire.comSkye And Arecor Partner To Develop Advanced Nimacimab Formulation For Obesity TreatmentMay 21, 2025 | nasdaq.comArecor shares climb 18% on collaboration with Skye BioscienceMay 19, 2025 | lse.co.ukSkye Bioscience, Inc.: Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate NimacimabMay 19, 2025 | finanznachrichten.deSkye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate NimacimabMay 19, 2025 | globenewswire.comEnsign Peak Advisors Inc Sells 132,713 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE)Ensign Peak Advisors Inc lowered its holdings in shares of Skye Bioscience, Inc. (NASDAQ:SKYE - Free Report) by 14.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 767,287 shares of the compaMay 18, 2025 | marketbeat.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of "Buy" from AnalystsShares of Skye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) have been given a consensus rating of "Buy" by the six analysts that are covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective amongMay 16, 2025 | marketbeat.comSkye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 13, 2025 | globenewswire.comSkye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on ObesityMay 13, 2025 | globenewswire.comSkye Bioscience (NASDAQ:SKYE) Issues Quarterly Earnings ResultsSkye Bioscience (NASDAQ:SKYE - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.03.May 12, 2025 | marketbeat.comEarnings call transcript: Skye Bioscience Reports Q1 2025 Financials Amid R&D ExpansionMay 10, 2025 | investing.comSkye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comSkye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in ObesityMay 8, 2025 | globenewswire.comBraidwell LP Buys Shares of 825,732 Skye Bioscience, Inc. (NASDAQ:SKYE)Braidwell LP purchased a new stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 825,732 shares of the company's stock, valued at approximately $2,337,000May 8, 2025 | marketbeat.comSkye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025May 7, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Acquires 463,644 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE)Schonfeld Strategic Advisors LLC grew its holdings in Skye Bioscience, Inc. (NASDAQ:SKYE - Free Report) by 48.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,422,741 shares of the company's stock after purchasing an addMay 6, 2025 | marketbeat.comSkye Bioscience to Participate in May Investment and Medical ConferencesApril 29, 2025 | globenewswire.comSkye Bioscience announces inducement grant under Nasdaq listing ruleApril 28, 2025 | markets.businessinsider.comSkye Bioscience Inc.April 26, 2025 | barrons.comSkye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 25, 2025 | globenewswire.comWilliam Blair Predicts Skye Bioscience Q2 EarningsSkye Bioscience, Inc. (NASDAQ:SKYE - Free Report) - Equities research analysts at William Blair issued their Q2 2026 earnings estimates for Skye Bioscience in a report released on Tuesday, April 15th. William Blair analyst A. Hsieh expects that the company will post earnings per share of ($0.33)April 18, 2025 | marketbeat.comA Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash ValueApril 16, 2025 | seekingalpha.comSkye Bioscience announces new preclinical data for nimacimabApril 15, 2025 | markets.businessinsider.comSkye Bioscience Stock Rises on Preclinical Data for Weight Loss DrugApril 15, 2025 | marketwatch.comSkye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal ModelsApril 15, 2025 | benzinga.comSkye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical ModelApril 15, 2025 | globenewswire.comSkye Bioscience to Conduct Meetings at Piper Sandler ConferenceApril 14, 2025 | globenewswire.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by BrokeragesSkye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) has been assigned a consensus rating of "Buy" from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 1-year price objective among brokerageMarch 25, 2025 | marketbeat.comEarnings call transcript: Skye Bioscience Q4 2024 highlights financials, product progressMarch 22, 2025 | uk.investing.comSkye Bioscience (NASDAQ:SKYE) Price Target Cut to $14.00 by Analysts at Craig HallumCraig Hallum dropped their price target on shares of Skye Bioscience from $18.00 to $14.00 and set a "buy" rating on the stock in a research note on Friday.March 22, 2025 | marketbeat.comSkye Bioscience's (SKYE) "Outperform" Rating Reiterated at William BlairWilliam Blair restated an "outperform" rating on shares of Skye Bioscience in a research report on Friday.March 22, 2025 | marketbeat.comSkye Bioscience, Inc. (PNK:SKYE) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | insidermonkey.comSkye Bioscience, Inc.: Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 22, 2025 | finanznachrichten.deSkye Bioscience price target lowered to $14 from $18 at Craig-HallumMarch 22, 2025 | markets.businessinsider.comSkye Bioscience’s Positive Earnings Call Highlights Nimacimab ProgressMarch 21, 2025 | tipranks.comSkye Bioscience (NASDAQ:SKYE) Releases Earnings Results, Beats Estimates By $0.06 EPSSkye Bioscience (NASDAQ:SKYE - Get Free Report) issued its earnings results on Thursday. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.06.March 21, 2025 | marketbeat.comSkye Bioscience reports Q4 EPS (24c), consensus (24c)March 21, 2025 | markets.businessinsider.comSkye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment periodMarch 21, 2025 | msn.comSkye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 21, 2025 | finance.yahoo.comSkye Bioscience (NASDAQ:SKYE) Shares Down 31% - Time to Sell?Skye Bioscience (NASDAQ:SKYE) Stock Price Down 31% - Should You Sell?March 21, 2025 | marketbeat.comSkye Bioscience Reports 2024 Financial Results and Trial ProgressMarch 21, 2025 | tipranks.comSkye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comSkye Bioscience to Announce 2024 Financial Results on March 20th, 2025March 14, 2025 | globenewswire.comLeo Miller: Page 4March 7, 2025 | entrepreneur.com Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Email Address SKYE Media Mentions By Week SKYE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SKYE News Sentiment▼1.221.00▲Average Medical News Sentiment SKYE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SKYE Articles This Week▼73▲SKYE Articles Average Week Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GLUE News TNGX News CRVS News SLDB News IMMP News CYRX News ATXS News TSVT News AVIR News GOSS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SKYE) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
